New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
16:16 EDTGHDXGenomic Health sees FY13 EPS ex-items 48c-68c, consensus 28c
Sees FY13 revenue $258M-$266M, consensus $262.4M. The company said, "In 2013, we plan to continue to invest in near-term opportunities to expand our global breast and colon cancer businesses in order to drive top-line revenue growth, and in our prostate cancer launch to build long-term value, and expect losses in the first and second quarters." Sees FY13 GAAP EPS (12c)-8c and non-GAAP basic EPS, excluding stock compensation expense, 48c-68c.
News For GHDX From The Last 14 Days
Check below for free stories on GHDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2014
08:15 EDTGHDXGenomic Health announces two important international milestones
Genomic Health announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia agreed to fund the Oncotype DX breast cancer test for eligible patients, expanding reimbursement to more than 80% of the country's population. In Germany, updated guidelines from the AGO, or Gynecologic Oncology Working Group, now recommend the Oncotype DX breast cancer test as the only gene expression test to predict chemotherapy benefit in early-stage hormone receptor-positive invasive breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use